New patent for the use of estrogens in the treatment of DED to be issued in the US
July 23, 2020 1:04 pmThe US Patent and Trademark Office has issued a notice of allowance indicating that a new patent will be granted... View Article
The US Patent and Trademark Office has issued a notice of allowance indicating that a new patent will be granted... View Article
After publishing of topline results, CEO Martin Vidaeus gives an update regarding the RP101 Phase II results, current business development... View Article
On June 18, 2020, the Board of Directors of Redwood Pharma AB decided to take up a bridge loan totaling SEK 4.5... View Article
In connection with convertible bond issues during the period July 2018 – January 2019, Redwood Pharma issued 287,958 warrants expiring... View Article
Download the quarterly report Redwood Pharma AB (publ.) REDWOODPHARMA.SE, Spotlight Stock Market ticker: REDW 1 January – 31 March 2020... View Article
Redwood Pharma and Prof. Gerhard Garhöfer of the Medical University of Vienna, Austria invite you to listen to the live... View Article
RP101 demonstrates efficacy and safety in Phase II study of patients with moderate-to-severe dry eye disease RP101 more than doubles... View Article
Redwood Pharma will present on March 24 in Paris, France, at BIO-Europe Spring, one of Europe’s largest life science partnership... View Article
SPOTLIGHT STOCK MARKET: REDW REDWOODPHARMA.COM 1 January – 31 December 2019 Net revenue for the period was SEK... View Article
The China National Intellectual Property Administration (CNIPA) has communicated its intention to grant a new patent in China in the... View Article